Christopher Thibodeau has been named chief operating officer of OncoCell MDx. He joins Mark McDonough, recently appointed as OncoCell’s president, chief executive officer, and member of the board of directors, in strengthening the company’s executive leadership team.
More than a year after a catastrophic shortage of platinum-based chemotherapy drugs swept through the U.S., FDA on June 28 officially removed carboplatin and cisplatin from the drug shortage list.
